{"name":"Pila Pharma","slug":"pila-pharma","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxOdHFPUUZuellybkRENllwN0c2a01SaGdRRmtZRG9yeVJ4eVoxamJYa1E4T0tHeDBTVnpXdG9aQjJ6aUxGVnVjcU12a2tKcDNseG5QSFAxSE5qM29rTWFub3FldXNSRjB2bTdaWG9SU1JZeXBuT3pIOVVMdVFyVlVRQ05mMVBEZDlFOF9UcVNUNU9NNWZySTdfRE1pOWlXMktkUG12cUxGVTBMdUhtU0xNN1lHYXlzTk1Cb0E?oc=5","date":"2026-03-25","type":"pipeline","source":"TradingView","summary":"Pila Pharma updates from Bio-Europe Spring in Lisbon - TradingView","headline":"Pila Pharma updates from Bio-Europe Spring in Lisbon","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxQS1dlMkxzYkhTN0QzVFVVSHBUYWt4N3hrRlRPOFBJMXllWUMyZFBsNlVfSWduVHhNVWx1cDNaaEVIRkVBa3FCbHBLSHBWTjRDcjc3bkVlb0hmaEhSR25Wa2VkQm9Ib0MtM3FPYmdMbkNxbzVnRklhN3dkemxKVlVnTEZzM2Fscm9ZSFN0QzRhTUNVTGFHVkVteC1hSDVMZ2ZnRHo1T0g3MWtXaThjLVpmcy1QUQ?oc=5","date":"2026-03-19","type":"pipeline","source":"marketscreener.com","summary":"Pila Pharma postpones annual report and shareholders' meeting - marketscreener.com","headline":"Pila Pharma postpones annual report and shareholders' meeting","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxOeTMybzhtbWl4c09iWjc2dmw4d3BfU3lkYnZMcUlfUUp2ZUtOZ01WVFlXc3NrTzZXX0JwRld4UFNKTV8wNTQ2NFdKYmlSQ1dYY1JMSHQ1QW5EamtuaHR3d1N4dFZmbFBxY2Q2WEdiRkg1ancxMUo5OTB1b1lZWVdQXzhIbFg2eHMxUkQ5QUFtQWZuNmk2TmlBLVRmVDljWEtFOUZMcVUtcURCaklmdGw4UHNzR1Z0ZUdWd2xlNlEwc21Nd05S?oc=5","date":"2026-03-05","type":"pipeline","source":"beQuoted","summary":"PILA PHARMA: TO2 WARRANTS CONVERTED, SHARES ARE NOW TRADABLE - CEO & FOUNDER'S PARTICIPATION DISCLOSED - beQuoted","headline":"PILA PHARMA: TO2 WARRANTS CONVERTED, SHARES ARE NOW TRADABLE - CEO & FOUNDER'S PARTICIPATION DISCLOSED","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxQekFaRDBkbzVSZ3lCaWRYS0Z0WWhROEhkN3Mtd0RPWDhpeExjNmtqdTdWSHEzbFR3QktiMnhEWEJRaVZfSEIxaGpNV1JMNDVhdXhxT0Q0bEZvd3lpS3dHdy1mdXRSUzhFdU8tc214QmNzc3N3N3pxY1VlWlFpMzYyWXYzb0psRnNLQ3NqbENtSGxIeC1GRzBnVE5hYw?oc=5","date":"2026-02-18","type":"pipeline","source":"analystgroup.se","summary":"Comment on the Outcome of Pila Pharma’s Series TO2 Warrants - analystgroup.se","headline":"Comment on the Outcome of Pila Pharma’s Series TO2 Warrants","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1wFBVV95cUxNa1hISVZfSmVORUt1ZTNYeTRKMnAxS1JpaHdfVWJQeE5COGhTQkRxWFVxOGdCOTktME03cWliaVVsWG9qdTNQMjBZOHZ3MC1CODJvTlNMNjRMOFVvcmZEcHN4TGlVTm1OajctSlo1ZEJBc3VuVHJ5bTMwRHo1V1FkTGlKRDRzQmkzLURXUTJqQXlxWGMxSENhWGdLbUFzeFZfWmZPaTRTZElXRmFnRFpQa0s1VVZHamlsNWZCSFRMWjdMT1dmREJ1ZlgzOUN0US01ZFM0SG56VQ?oc=5","date":"2026-02-18","type":"trial","source":"TradingView","summary":"Pila Pharma boosts financial runway and fully funds clinical obesity study - TradingView","headline":"Pila Pharma boosts financial runway and fully funds clinical obesity study","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxOOHRPc0RuNk95aHpDZm5JWlN6VGQyX1FIT3VTTUxxOS03WWhVZkhlS1VFVVczVVRzdjRTVTZxbjVoOGVSbWNTSHBmQzBYRlVJMHJCeFFPZGxoakVINFF6ZzhOR3FjeW9UY3NkOElpcHFvdVlEZ182eXB1MGJUcFl6SjZZYzkzdkZSZDlUajFVVnUyYk40UklhZG93TUdzLUJtRjZzOF9oblFHU3ZTQi0xbGNhOHFuRjJ2VTZTQTlvZ3d3SGM?oc=5","date":"2026-01-05","type":"pipeline","source":"beQuoted","summary":"PILA PHARMA: INVITED TO PRESENT AT BIOTECH SHOWCASE / J.P MORGAN HEALTHCARE WEEK IN SAN FRANCISCO, JANUARY 13, 2026 - beQuoted","headline":"PILA PHARMA: INVITED TO PRESENT AT BIOTECH SHOWCASE / J.P MORGAN HEALTHCARE WEEK IN SAN FRANCISCO, JANUARY 13, 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxQdm1vMzdhNjlMejdnRHFYWlAtV0QxYXpoR3A4Z1hMYmtyS3F3OXR5LUNnYl9IUmsySUZkSVlmSHVPZHgxLU5OdERncnlyWmZrUEEtbENDXzk2Um9pR2lvMUlUVmZPSTRrZUhaVHV2Sk1pb25pY1BSTzhoVENUSTFnUXpMR3lqdndjQ29lS2x3a3dsM2s0blhqWkxSejQ?oc=5","date":"2025-11-05","type":"pipeline","source":"Biostock","summary":"Pila Pharma stands out in next-generation obesity pipeline - Biostock","headline":"Pila Pharma stands out in next-generation obesity pipeline","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxNSUFyeTdLMFJjX1U4b2VPMkItMTQ5R09pOHBCQnZSTVl1NnRPVjRPNjR2eDFocGxEMERwWlZQZm5IemJvaHdzbnRjU1M3SmZGUFZYczNhdUlPQklfVGpUdlYyTXpkYWY5TWJzQWdRMkZpVTFMRXRZS0gzdzB2UE9tczNkdmxqQ2c?oc=5","date":"2025-11-03","type":"pipeline","source":"Yahoo Finance UK","summary":"Pila Pharma share issue for obesity drug research is massively oversubscribed - Yahoo Finance UK","headline":"Pila Pharma share issue for obesity drug research is massively oversubscribed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1gFBVV95cUxOaUFQeUtuZ3l6OTJxcGNkUHN5and4eXh0MlZfbl9aeDc4ZXdjbnp0b29RclhRSnRidEhod1lSTW10eGhMSlhRd1gyazVOVkd2dExKODBucU1RdmF1NnRFczVZcjZXSlJhN25VTlJxNS1MUl9iZVpyRWM0WXRBWVZGM2VsaGpreVdGb2p1TkN0eDA1Ynk3bGRvOVBKQWlLYkUydFlJWmh2OVJ3dVFVVG9MZE40QTRvMGx3d3Vld1dqYllReVYwTGhSaC1DcWhlLUxFNlg4MkxB?oc=5","date":"2025-11-03","type":"pipeline","source":"Mynewsdesk","summary":"Pila Pharma’s capital raise oversubscribed by 293 percent to fund obesity studies - Mynewsdesk","headline":"Pila Pharma’s capital raise oversubscribed by 293 percent to fund obesity studies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxPc0pSWno2Y0h5dG43Y1BKWkpJWHRjdU5XQ2MzaGhQUk9lWmE3STVLNFQ3OFFzUHRXQ3B1TFc0aURmYkRCQ2NxMEFxSXZwV1FzZ2NmZWE1d254ZGRqZjBDT3JyYnVIUWdmeDBPdllBWVlGTVd6ZzluN3B4LVduTHA2cFJqWWF3dDVwZHFDbVZGVHNwbDRqRkZ4Q0VxQmstUzhfWXh2alpDNUI?oc=5","date":"2025-10-06","type":"trial","source":"Biostock","summary":"PILA PHARMA partners with Gubra for preclinical obesity trials - Biostock","headline":"PILA PHARMA partners with Gubra for preclinical obesity trials","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxOUm5wSkRpUWZMeDUxYmExOS1makg1ZTNLeEp0N2Q4d0lWSWZ4VmlhWUFJLVFGZnVZSnl2eGtLM0luMW9GQ1YyRmJZRFZiVVR6am8ydXFvOFZjbzlzc3lnMnR1SGtubkw3S3hyY1MyWFpzcDBxa3ZaaDJlZ1ViVmFfWEtjWU9VT0xRNEk2Qg?oc=5","date":"2025-07-10","type":"pipeline","source":"Manufacturing Chemist","summary":"Pila Pharma bags nearly £1.5m to aid obesity drug development - Manufacturing Chemist","headline":"Pila Pharma bags nearly £1.5m to aid obesity drug development","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxNSGhGOTlyb2V0V3pmR2xIazdjOTF5UDVOcVNyeXMzNnJDaFh5c1VjS3hVMlBEakVFSUZpTVVIVGRCTlIwenNnZWM3WS14YnRWNGJoSkdmb1BBc0M5LWtpM3BiQ3Nhcm45VXZZcTA2bnRUeFc5eWVwZF9jeEJPUFJUc0JXbDIzbFhZS2prY0dxQ0wxZDVqWklJSA?oc=5","date":"2025-07-08","type":"pipeline","source":"Pharmafile","summary":"Pila Pharma raises SEK 20m to advance new oral obesity treatment - Pharmafile","headline":"Pila Pharma raises SEK 20m to advance new oral obesity treatment","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}